Clinical trials: GI Disorders
Regurgitation, Gastric, Diarrhea
To Assess the Safety and Tolerance of Infant Formula With Locust Bean Gum in Infants With Regurgitation
A randomized, controlled study to evaluate the safety and tolerance of an infant formula with locust bean gum in infants with regurgitation. (Solar)
- Trial name
- Solar (NCT04042454)
- Testing
- milk based anti-regurgitation infant formula, Milk based infant formula
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Ulcerative Colitis
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis
- Trial name
- NCT00449722
- Testing
- mesalazine
- Where
- Germany
- Volunteers
- 380 people
- Sponsor
- Dr. Falk Pharma GmbH
Esophageal Cancer
Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field (PEF) treatment of advanced or unresectable esophageal squamous cell carcinoma patients.
- Trial name
- NCT06756841
- Testing
- PEF treatment
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Energenx Medical LTD.
Ulcerative Colitis
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
The purpose of this study is to evaluate efficacy and safety of PF-06826647 in moderate to severe ulcerative colitis
- Trial name
- NCT04209556
- Testing
- PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD
- Where
- 24 sites in United States
- Sponsor
- Pfizer
Irritable Bowel Syndrome
IBS Skin Patch Test Food Allergy Study
Participants with IBS are skin patch tested (no needles) to 80 different foods and food additives, compounded for patch testing, in search of food allergies. The testing requires 3 office visits within a 4 or 5 day period.
- Trial name
- NCT06288672
- Testing
- True avoidance diet
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- IBS-80, LLC
Gastrointestinal Diseases
Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms
Study to evaluate efficacy and tolerability of Buscopan® plus versus Buscopan®, paracetamol, and placebo in patients with painful gastric or intestinal spasms.
- Trial name
- NCT02229786
- Testing
- Buscopan® plus, Buscopan®, Paracetamol
- Volunteers
- 1,637 people
- Sponsor
- Boehringer Ingelheim
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Inflammatory Bowel Disease
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease
The study is a prospective, non-controlled, open-label multi-centre pilot safety study of iron isomaltoside 1000 (Monofer®) administered to subjects with anaemia and Inflammatory Bowel Disease (IBD).
- Trial name
- IBD-02 (NCT01599702)
- Testing
- Iron Isomaltoside 1000
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Pharmacosmos A/S
Colorectal Cancer
Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages
The NICE study is a prospective, multi-site study to train and validate a blood-based, glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and associated relevant…
- Trial name
- NICE (NCT05445570)
- Testing
- Non-Interventional
- Where
- 12 sites in United States
- Volunteers
- 3,002 people
- Sponsor
- Venn Biosciences Corporation
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Rectal Neoplasms
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer
The purpose of this phase II trial is to determine the efficacy and safety of the combination of oxaliplatin, capecitabine and radiotherapy as preoperative therapy in locally advanced cancers of the rectum.
- Trial name
- PROCTFUL (NCT00263029)
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Volunteers
- 18 people
- Sponsor
- Sanofi
Gastroesophageal Reflux Disease
Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease
The purpose of this study is to evaluate treatment in Gastroesophageal Reflux Disease (GERD) patients (aged 18~75) with endoscopically proven GERD treated with AGSPT201 Tablet.
- Trial name
- AGSPT (NCT01400945)
- Testing
- AGSPT201 Tab contains S-pantoprazole
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Colorectal Cancer
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than…
- Trial name
- NCT00207051
- Testing
- Brivanib + Cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Gastric Ulcer
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.
- Trial name
- MGES (NCT01150162)
- Testing
- Rebamipide and Omeprazole, Omeprazole
- Where
- 3 sites in Pakistan
- Volunteers
- 129 people
- Sponsor
- Otsuka Pakistan Limited
Duodenal Ulcer
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
This is a multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50mg comparing with Lansoprazole 30 mg after the…
- Trial name
- NCT05010954
- Testing
- LXI-15028 50mg group, Lansoprazole 30mg group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Irritable Bowel Syndrome
Effect of Probiotic Supplement on Bowel Function
The purpose of this study is to analyse the effect of probiotic supplement on symptoms of irritable bowel syndrome.
- Trial name
- IBS2 (NCT01475929)
- Testing
- Probiotic supplement
- Where
- Finland
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Danisco
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.